The effects of bevacizumab on postoperative complications in patients undergoing colorectal and pancreatic cancer resection

E C Cheon; W Small Jr; M J Strouch; S B Krantz; A Rademaker; M F Mulcahy; A B Benson; D J Bentrem; M S Talamonti

doi:10.1002/jso.21598

The effects of bevacizumab on postoperative complications in patients undergoing colorectal and pancreatic cancer resection

J Surg Oncol. 2010 Oct 1;102(5):539-42. doi: 10.1002/jso.21598.

Authors

E C Cheon¹, W Small Jr, M J Strouch, S B Krantz, A Rademaker, M F Mulcahy, A B Benson, D J Bentrem, M S Talamonti

Affiliation

¹ Department of Surgery, Mount Sinai Hospital, University of Illinois at Chicago, Chicago, Illinois, USA.

PMID: 20812264
DOI: 10.1002/jso.21598

Abstract

Bevacizumab (Avastin™; rhuMab VEGF), a monoclonal antibody targeting vascular endothelial growth factor (VEGF), has seen increased use in the perioperative treatment of colorectal and pancreatic cancer. Little is known, however, regarding its impact on surgical outcomes in patients undergoing resection. The objective of this review was to examine if the addition of bevacizumab to existing neoadjuvant regimens increases morbidity after cancer resection.

Publication types

Evaluation Study
Research Support, Non-U.S. Gov't
Review

MeSH terms

Angiogenesis Inhibitors / administration & dosage
Angiogenesis Inhibitors / adverse effects*
Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal / adverse effects*
Antibodies, Monoclonal, Humanized
Bevacizumab
Colorectal Neoplasms / drug therapy*
Colorectal Neoplasms / surgery
Humans
Neoadjuvant Therapy
Pancreatic Neoplasms / drug therapy*
Pancreatic Neoplasms / surgery
Postoperative Complications
Treatment Outcome

Substances

Angiogenesis Inhibitors
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Bevacizumab